
An mRNA Cancer Vaccine Just Cut Melanoma Recurrence by 42% - Here Is Why That Matters to You
A Phase 3 trial found adding a personalized mRNA cancer vaccine to Keytruda cut melanoma recurrence or death risk by 42%. The result is a preview of personalized oncology, but it is not yet approved and carries real cost and access questions. For younger readers, the practical takeaway is that sun damage compounds, so sunscreen and early skin checks still matter.


